The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Diabetic retinopathy: Looking forward to 2030
Open accessAbstract
Diabetic retinopathy (DR) is the major ocular complication of diabetes mellitus, and is a problem with significant global health impact. Major advances in diagnostics, technology and treatment have already revolutionized how we manage DR in the early part of the 21 st century. For example, the accessibility of imaging with optical coherence tomography, and the development of anti-vascular endothelial growth factor (VEGF) treatment are just some of the landmark developments that have shaped the DR landscape over the last few decades. Yet, there are still more exciting advances being made. Looking forward to 2030, many of these ongoing developments are likely to further transform the field. First, epidemiologic projections show that the global burden of DR is not only increasing, but also shifting from high-income countries towards middle- and low-income areas. Second, better understanding of disease pathophysiology is placing greater emphasis on retinal neural dysfunction and non-vascular aspects of diabetic retinal disease. Third, a wealth of information is becoming available from newer imaging modalities such as widefield imaging systems and optical coherence tomography angiography. Fourth, artificial intelligence for screening, diagnosis and prognostication of DR will become increasingly accessible and important. Fifth, new pharmacologic agents targeting other non-VEGF-driven pathways, and novel therapeutic strategies such as gene therapy are being developed for DR. Finally, the classification system for diabetic retinal disease will need to be continually updated to keep pace with new developments. In this article, we discuss these major trends in DR that we expect to see in 2030 and beyond.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gulshan, V., Peng, L., Coram, M., Stumpe, M. C., Wu, D., Narayanaswamy, A., Venugopalan, S., Widner, K., Madams, T., Cuadros, J., et al. (2016) · JAMA · doi:10.1001/jama.2016.17216 · Cited by 7,697
Global prevalence and major risk factors of diabetic retinopathy
Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A., Grauslund, J., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1909 · Cited by 4,985
Self-citationWilkinson, C. P., Ferris, F. L., Klein, R. E., Lee, P. P., Agardh, C. D., Davis, M., Dills, D., Kampik, A., Pararajasegaram, R., & Verdaguer, J. T. (2003) · Ophthalmology · doi:10.1016/s0161-6420(03)00475-5 · Cited by 3,743
Clinically applicable deep learning for diagnosis and referral in retinal disease
De Fauw, J., Ledsam, J. R., Romera-Paredes, B., Nikolov, S., Tomasev, N., Blackwell, S., Askham, H., Glorot, X., O’Donoghue, B., Visentin, D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0107-6 · Cited by 2,639
Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045
Teo, Z. L., Tham, Y.-C., Yu, M., Chee, M. L., Rim, T. H., Cheung, N., Bikbov, M. M., Wang, Y. X., Tang, Y., Lu, Y., et al. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2021.04.027 · Cited by 2,420
Self-citationTing, D. S. W., Cheung, C. Y.-L., Lim, G., Tan, G. S. W., Quang, N. D., Gan, A., Hamzah, H., Garcia-Franco, R., San Yeo, I. Y., Lee, S. Y., et al. (2017) · JAMA · doi:10.1001/jama.2017.18152 · Cited by 2,402
Self-citation(1991) · Ophthalmology · doi:10.1016/s0161-6420(13)38012-9 · Cited by 2,048
Abràmoff, M. D., Lavin, P. T., Birch, M., Shah, N., & Folk, J. C. (2018) · npj Digital Medicine · doi:10.1038/s41746-018-0040-6 · Cited by 1,638
Ranibizumab for Diabetic Macular Edema
Nguyen, Q. D., Brown, D. M., Marcus, D. M., Boyer, D. S., Patel, S., Feiner, L., Gibson, A., Sy, J., Rundle, A. C., Hopkins, J. J., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.12.039 · Cited by 1,621
Artificial intelligence and deep learning in ophthalmology
Ting, D. S. W., Pasquale, L. R., Peng, L., Campbell, J. P., Lee, A. Y., Raman, R., Tan, G. S. W., Schmetterer, L., Keane, P. A., & Wong, T. Y. (2019) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2018-313173 · Cited by 1,554
Self-citation
Cited by
A deep learning system for predicting time to progression of diabetic retinopathy
Dai, L., Sheng, B., Chen, T., Wu, Q., Liu, R., Cai, C., Wu, L., Yang, D., Hamzah, H., Liu, Y., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02702-z · Cited by 339
Self-citationMłynarska, E., Czarnik, W., Dzieża, N., Jędraszak, W., Majchrowicz, G., Prusinowski, F., Stabrawa, M., Rysz, J., & Franczyk, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031094 · Cited by 328
Yang, Q., Bee, Y. M., Lim, C. C., Sabanayagam, C., Yim-Lui Cheung, C., Wong, T. Y., Ting, D. S. W., Lim, L.-L., Li, H., He, M., et al. (2025) · eClinicalMedicine · doi:10.1016/j.eclinm.2025.103089 · Cited by 38
Self-citationWang, Z., Li, Z., Li, K., Mu, S., Zhou, X., & Di, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1197783 · Cited by 27
Moannaei, M., Jadidian, F., Doustmohammadi, T., Kiapasha, A. M., Bayani, R., Rahmani, M., Jahanbazy, M. R., Sohrabivafa, F., Asadi Anar, M., Magsudy, A., et al. (2025) · BioMedical Engineering OnLine · doi:10.1186/s12938-025-01336-1 · Cited by 18
Metadata
- Authors
- Tan, T.-E., & Wong, T. Y.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2023-01-09
- Volume
- 13
- Pages
- 1077669-1077669
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W4313827473
- Cited by
- 511
- References
- 82
- FWCI
- 105.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diabetic retinopathy: Looking forward to 2030. https://app.cochat.ai/papers/10.3389/fendo.2022.1077669
- The paper
- Tan, T.-E., & Wong, T. Y. (2023). Diabetic retinopathy: Looking forward to 2030. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2022.1077669
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.